Marco Insights delivers governments, pharmaceutical companies and public health organizations aggregated, anonymized data on consultation patterns, diagnostic challenges and recurring therapeutic questions in Gastric Cancer across countries and regions. The insights enable evidence-based policy, investment and therapeutic strategies.
Some answers to questions we often receive
Marco Insights aggregates anonymized data on Gastric Cancer consultation frequency, distribution of molecular subtypes queried, treatment-by-line question patterns, regions with highest diagnostic uncertainty and gaps between local practice and NCCN/ESMO guidelines, updatable in real time by country.
Yes. Marco Insights automatically cross-references Gastric Cancer physician query patterns with current guideline recommendations, identifying areas where clinical practice deviates from standard: molecular underdiagnosis, suboptimal biomarker use or underutilization of targeted therapies with clear indication.
Marco Insights updates in real time with every new Marco system interaction on Gastric Cancer. Dashboards reflect data from the selected period (week, month, quarter), enabling detection of emerging trends such as the impact of a new regulatory approval or published guideline.
Marco Insights lets pharma companies understand real-world penetration of their products in Gastric Cancer, identify the most frequent physician questions about their molecules, detect adoption barriers by region or institution type, and orient medical and access programs based on actual market needs.
Marco Insights dashboards can be segmented by country, region, institution type (public hospital, private clinic, primary care) and medical specialty, allowing governments and pharma to compare Gastric Cancer management across different healthcare contexts and prioritize interventions.
Marco Insights works exclusively with aggregated, anonymized data. No data allows identification of individual patients, institutions or specific physicians without consent. The system complies with applicable data protection regulations and provides data processing agreements for each client.
Commercial strategies for gastric cancer are designed without data on HER2/MSI testing rates or the most common clinical questions by market.